Harmony Biosciences to Present New Data on EPX-100 for Dravet Syndrome Next Week at American Epilepsy Society Annual Meeting.

Harmony Biosciences will present new data from its ongoing ARGUS trial on EPX-100 for Dravet syndrome at the American Epilepsy Society Annual Meeting. The trial includes a 4-week observational period, a 16-week double-blind period, and an open-label extension period. EPX-100 is an adjunctive therapy being evaluated for efficacy and safety in children and adults with Dravet syndrome. The company expects topline data in 2026.